News - UF Innovate

Skin Cancer Vaccine Developed by Tampa Company Enters Phase 1 of Clinical Trial

UF startup and UF Innovate | Sid Martin Biotech alum Morphogenesis, Inc. completed its first-in-human phase one trial in cutaneous melanoma at Moffitt Cancer Center within the past year and has now moved into studying patients in earlier stages of skin cancers.

UF Health Researcher Answers Top Questions About the New COVID-19 Vaccines

The leading COVID-19 vaccines aren’t anything like the polio vaccination your grandparents received — or even the flu shot you got this fall. A look under the hood unveils a remarkable advancement in medicine.

Tapeworm, Vertigo and Pancreatitis Drugs Are Being Trialled As COVID-19 Treatments

Included in this news roundup is UF startup Algernon Pharmaceuticals's trials with ifenprodil, a drug used to treat vertigo and bird flu. Algernon is testing the drug's efficacy in preventing lung damage and increasing survivability in patients with COVID-19.

Group of Crimefighters Using VR, Help From Former Crooks To Cut Down Shoplifting

UF Innovate | The Hub's Loss Prevention Research Council is fighting crime by working with former thieves to create VR simulations to help major retailers prevent theft.

Research Underway To Treat COVID-19 Long Hauler Syndrome

In this article, UF Innovate | Sid Martin Biotech resident client Neobiosis founder Ian White explains how his company is using regenerative medicine to develop products to treat coronavirus long hauler syndrome. (Note: the University of Florida Innovate Center mentioned in the story should be UF Innovate | Sid Martin Biotech.)

UF Health Researchers Win $75 Million Grant To Help Develop New Antibiotic

In the medical and military fields, antibiotic-resistant bacteria can be formidable foes. Now, University of Florida Health researchers and their collaborators have a $75 million grant to identify a new, unique antibiotic that will protect public health.

New Resident Client at Sid Martin Biotech to Pave Way for Post-COVID Therapy, Regenerative Medicine Research

The inflammation COVID-19 patients suffer during and post-COVID-19 infection (AKA "Post-COVID Syndrome") will be one of many focuses of a new resident client that recently joined the UF Innovate | Sid Martin Biotech, the world-recognized leader in biotechnology incubation. Neobiosis, which produces regenerative tissues, cells, and extracellular vesicles for research and clinical trials to help the body heal itself—without surgery—will operate a laboratory at the biotech center, located in Alachua.

How Will $1 Million in Artificial Intelligence Research Impact Florida Industry?

The University of Florida announced a $1 million investment into artificial intelligence. Twenty faculty teams will study wide-ranging uses on data analysis in a range of fields from agriculture to education.

Algernon Pharmaceuticals Receives Green Light from DSMB to Conduct Phase 3 Study of Ifenprodil for COVID-19

UF startup Algernon Pharmaceuticals Inc., formerly known as Breathtec Biomedical, a clinical-stage pharmaceutical development company, announced that the external Data and Safety Monitoring Board (“DSMB”) has completed its latest review of the Phase 2b part of the Company’s Phase 2b/3 human study of NP-120 (Ifenprodil) for the treatment of COVID-19, and has provided approval for the company to continue on with the Phase 3 part of the study.

Pear, etectRx To Explore Use of Sensors To Help Patients Stick With Digital Therapeutics

Pear Therapeutics is teaming up with UF Innovate | The Hub startup etectRx in a "first of its kind" collaboration examining the use of digital pill solutions with prescription digital therapeutics (PDTs), the latter company announced. As part of the agreement, whose financial terms were not disclosed, the companies will work on developing up to two central nervous system product candidates combining PDTs and adherence sensors.

UF News